Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC
This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort (616 KB)
: For those who stopped the medication, the median time until they did so was only 7 months . Toxicities and outcomes of 616 ibrutinib-treated patients in
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). available through PubMed Central (PMC)
If you're interesting in getting into color grading check out the "Filmmakers Powergrade". The powergrade was created inside of DaVinci Resolve for my latest project you can read more about the Filmmakers Powergrade here.
